Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 21 | 2023 | 295 | 4.420 |
Why?
|
| Infection Control | 14 | 2022 | 163 | 2.960 |
Why?
|
| Enterobacteriaceae Infections | 8 | 2021 | 56 | 2.330 |
Why?
|
| Klebsiella pneumoniae | 10 | 2022 | 70 | 1.980 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 5 | 2021 | 20 | 1.830 |
Why?
|
| Bacteremia | 6 | 2019 | 96 | 1.620 |
Why?
|
| beta-Lactamases | 10 | 2020 | 95 | 1.590 |
Why?
|
| Bacterial Proteins | 9 | 2020 | 87 | 1.500 |
Why?
|
| Klebsiella Infections | 9 | 2022 | 64 | 1.490 |
Why?
|
| Intensive Care Units | 8 | 2024 | 250 | 1.470 |
Why?
|
| Medical Informatics | 2 | 2021 | 10 | 1.270 |
Why?
|
| Population Surveillance | 6 | 2018 | 113 | 1.260 |
Why?
|
| Staphylococcal Infections | 4 | 2018 | 150 | 1.180 |
Why?
|
| Carrier State | 7 | 2024 | 60 | 1.080 |
Why?
|
| Public Health Surveillance | 2 | 2021 | 10 | 0.890 |
Why?
|
| Catheter-Related Infections | 3 | 2014 | 22 | 0.880 |
Why?
|
| Communicable Diseases | 1 | 2023 | 21 | 0.850 |
Why?
|
| Clostridium Infections | 1 | 2023 | 21 | 0.850 |
Why?
|
| Humans | 46 | 2024 | 25165 | 0.830 |
Why?
|
| Hospitals | 11 | 2023 | 161 | 0.820 |
Why?
|
| Disease Outbreaks | 3 | 2022 | 78 | 0.800 |
Why?
|
| Virus Diseases | 1 | 2022 | 9 | 0.790 |
Why?
|
| Subacute Care | 1 | 2021 | 6 | 0.760 |
Why?
|
| Disease Notification | 2 | 2018 | 5 | 0.680 |
Why?
|
| Chlorhexidine | 3 | 2023 | 57 | 0.630 |
Why?
|
| Pyomyositis | 2 | 2009 | 5 | 0.620 |
Why?
|
| Baths | 2 | 2018 | 26 | 0.590 |
Why?
|
| Chicago | 11 | 2024 | 916 | 0.580 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 112 | 0.540 |
Why?
|
| Enterobacteriaceae | 2 | 2015 | 43 | 0.530 |
Why?
|
| Skilled Nursing Facilities | 4 | 2021 | 30 | 0.490 |
Why?
|
| Skin | 3 | 2018 | 114 | 0.480 |
Why?
|
| Blastomycosis | 2 | 2020 | 23 | 0.480 |
Why?
|
| Illinois | 7 | 2021 | 231 | 0.470 |
Why?
|
| Hospital Information Systems | 1 | 2014 | 5 | 0.470 |
Why?
|
| Patient Care | 1 | 2013 | 30 | 0.420 |
Why?
|
| Middle Aged | 17 | 2024 | 8303 | 0.400 |
Why?
|
| Carbapenems | 5 | 2021 | 44 | 0.400 |
Why?
|
| Male | 21 | 2024 | 13813 | 0.390 |
Why?
|
| Community-Acquired Infections | 2 | 2012 | 66 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 348 | 0.360 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 28 | 0.350 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 29 | 0.340 |
Why?
|
| Ecosystem | 2 | 2021 | 24 | 0.340 |
Why?
|
| Registries | 3 | 2020 | 173 | 0.340 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 55 | 0.340 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2024 | 59 | 0.340 |
Why?
|
| Disease Transmission, Infectious | 2 | 2021 | 18 | 0.330 |
Why?
|
| Extremities | 1 | 2009 | 23 | 0.320 |
Why?
|
| Blastomyces | 1 | 2009 | 12 | 0.320 |
Why?
|
| Adult | 13 | 2024 | 7259 | 0.320 |
Why?
|
| Prevalence | 5 | 2018 | 428 | 0.310 |
Why?
|
| Retrospective Studies | 6 | 2023 | 3185 | 0.310 |
Why?
|
| Female | 18 | 2024 | 14160 | 0.300 |
Why?
|
| Neutropenia | 1 | 2008 | 11 | 0.300 |
Why?
|
| Public Health | 2 | 2021 | 64 | 0.300 |
Why?
|
| Anus Diseases | 1 | 2008 | 2 | 0.300 |
Why?
|
| Ulcer | 1 | 2008 | 5 | 0.300 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 65 | 0.290 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 53 | 0.270 |
Why?
|
| Sepsis | 1 | 2008 | 109 | 0.270 |
Why?
|
| Aged | 12 | 2024 | 8448 | 0.260 |
Why?
|
| Candida glabrata | 1 | 2005 | 1 | 0.250 |
Why?
|
| Fungemia | 1 | 2005 | 7 | 0.250 |
Why?
|
| Candidiasis | 1 | 2005 | 17 | 0.250 |
Why?
|
| Critical Illness | 2 | 2018 | 113 | 0.250 |
Why?
|
| United States | 6 | 2021 | 1928 | 0.250 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 30 | 0.240 |
Why?
|
| Critical Care | 2 | 2023 | 112 | 0.230 |
Why?
|
| Multilocus Sequence Typing | 2 | 2021 | 17 | 0.220 |
Why?
|
| Health Facilities | 1 | 2023 | 22 | 0.210 |
Why?
|
| Hospital Administration | 2 | 2021 | 22 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.210 |
Why?
|
| Long-Term Care | 4 | 2017 | 58 | 0.210 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 134 | 0.190 |
Why?
|
| Catheterization, Central Venous | 2 | 2014 | 36 | 0.190 |
Why?
|
| Phylogeny | 1 | 2021 | 46 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 82 | 0.190 |
Why?
|
| Computers | 1 | 2021 | 17 | 0.190 |
Why?
|
| Occupational Exposure | 1 | 2021 | 16 | 0.180 |
Why?
|
| Rectum | 5 | 2024 | 50 | 0.180 |
Why?
|
| Candida | 1 | 2020 | 15 | 0.180 |
Why?
|
| Clinical Protocols | 1 | 2021 | 56 | 0.180 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 13 | 0.180 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 641 | 0.170 |
Why?
|
| Hospitalization | 2 | 2014 | 284 | 0.170 |
Why?
|
| Algorithms | 2 | 2014 | 338 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 220 | 0.170 |
Why?
|
| Health Personnel | 1 | 2021 | 90 | 0.170 |
Why?
|
| Otitis Media | 1 | 2020 | 4 | 0.170 |
Why?
|
| Skull Base | 1 | 2020 | 33 | 0.160 |
Why?
|
| Risk Factors | 4 | 2021 | 2179 | 0.150 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 138 | 0.140 |
Why?
|
| Time Factors | 2 | 2013 | 1336 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 138 | 0.140 |
Why?
|
| Mass Screening | 1 | 2018 | 160 | 0.140 |
Why?
|
| Health Information Exchange | 1 | 2015 | 3 | 0.130 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 66 | 0.120 |
Why?
|
| Management Audit | 1 | 2014 | 2 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4508 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2010 | 1772 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 15 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2017 | 557 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2014 | 128 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 12 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 25 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 14 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2016 | 1618 | 0.100 |
Why?
|
| Bias | 1 | 2012 | 30 | 0.100 |
Why?
|
| Patient Transfer | 1 | 2012 | 20 | 0.100 |
Why?
|
| Genomics | 2 | 2022 | 53 | 0.090 |
Why?
|
| Ventilators, Mechanical | 2 | 2021 | 26 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2010 | 32 | 0.090 |
Why?
|
| Disease Reservoirs | 1 | 2010 | 9 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2010 | 94 | 0.090 |
Why?
|
| Research Design | 1 | 2012 | 175 | 0.090 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 7 | 0.090 |
Why?
|
| Hand Disinfection | 1 | 2010 | 25 | 0.090 |
Why?
|
| Enterococcus | 1 | 2010 | 55 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 121 | 0.080 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2009 | 1 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2009 | 7 | 0.080 |
Why?
|
| Lung Diseases, Fungal | 1 | 2009 | 10 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 30 | 0.080 |
Why?
|
| Quadriceps Muscle | 1 | 2009 | 31 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 6 | 0.080 |
Why?
|
| Gram-Positive Cocci | 1 | 2008 | 4 | 0.080 |
Why?
|
| Adolescent | 2 | 2018 | 2018 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 25 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2008 | 31 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 140 | 0.070 |
Why?
|
| Exotoxins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Leukocidins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 6 | 0.070 |
Why?
|
| Sexuality | 1 | 2008 | 14 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 231 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 25 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 26 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 566 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2008 | 318 | 0.070 |
Why?
|
| Penicillanic Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Piperacillin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 359 | 0.060 |
Why?
|
| Fluconazole | 1 | 2005 | 7 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2016 | 125 | 0.060 |
Why?
|
| Vancomycin | 1 | 2005 | 50 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 836 | 0.060 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2024 | 10 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 47 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1032 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 852 | 0.060 |
Why?
|
| Animals | 1 | 2012 | 3427 | 0.060 |
Why?
|
| HIV Infections | 1 | 2009 | 452 | 0.060 |
Why?
|
| Feces | 1 | 2024 | 88 | 0.060 |
Why?
|
| Feedback | 1 | 2023 | 30 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2024 | 137 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 6 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 9 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 43 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2023 | 41 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 450 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 7 | 0.050 |
Why?
|
| Georgia | 1 | 2021 | 11 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 17 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1301 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2021 | 78 | 0.040 |
Why?
|
| Itraconazole | 1 | 2020 | 4 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 186 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 38 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 200 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 181 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 133 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 318 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 324 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 64 | 0.040 |
Why?
|
| Skin Care | 1 | 2018 | 12 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 45 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1672 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 13 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 458 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 32 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 50 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 16 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 58 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 82 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 173 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 520 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 111 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 572 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2012 | 12 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 25 | 0.030 |
Why?
|
| Propensity Score | 1 | 2012 | 35 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 88 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 520 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2012 | 47 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 1813 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 55 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 249 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 103 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1085 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 49 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3204 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 58 | 0.020 |
Why?
|